OTPE WOOD OF TRADEMARK

IFW

16484

PATENT APPLICATION File No: 97-63C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Darrell C. Conklin, Hal Blumberg

Serial No. : 10/039,876

Group Art Unit : 1646 Examiner : Basi, N.S.

Filed : October 26, 2001

For : A HUMAN 2-19 PROTEIN HOMOLOGUE, Z219A

Date Submitted : October 27, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The present application is a continuation of U.S. Patent Application Serial No. 09/167,513, filed October 6, 1998, now U.S. Patent No. 6,388,064.

Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent and Trademark Office in a prior application identified herein.

Serial No. 10/039,876 Page 2

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

The Commissioner is hereby authorized to charge the fee under 37 C.F.R. §1.17(p) of \$180.00 to ZymoGenetics, Inc. Deposit Account No. 26-0290. A duplicate of this paper is enclosed.

Respectfully submitted,

Robyn Adams

Registration No. 44,495



PATENT APPLICATION

File No: 97-63C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

: Darrell C. Conklin, Hal Blumberg

Serial No.

: 10/039,876

Group Art Unit

: 1646

Examiner

: Basi, N.S.

Filed

: October 26, 2001

For

: A HUMAN 2-19 PROTEIN HOMOLOGUE, Z219A

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Information Disclosure Statement (in duplicate)
- 2. PTO-1449 Form (6 pages)
- 3. 0 References
- 4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

October 27, 2005.

Cynthia Hagen

FORM PT (REV 2-32)	-	U.S.DEP PATENT	PARTMEN' F AND TR		File No. 97-63C1		Serial No. 10/039,876		
INFORMATION OF PE	\ _\	DISCLOSURE Jse several she		CANT	Applicant(s): Darrell C. Conklin, Hal Blumberg				
OCT 8 1 200	Z \	ose severar sne		<i>y</i> /		Filing Date: Group: 1646 October 26, 2001			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	Al	6,388,064	5/14/02	Conklin et al.		536	23.5	10/6/98	
	1		FO	L REIGN PATE	NT DOCUM	ENTS			
Examiner Initial		DOCUMENT NUMBER	Date	Country		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	B1	WO 99/49023	9/30/99	PCT				3/18/99	
	A2			(Including Aut		ate, Pertine	ent Patents,	etc.)	
	A3	Jaco	Jacobs et al., <u>Gene 198</u> :289-296, 1997.						
	A4	Tash	Tashiro et al., <u>Science</u> <u>261</u> :600-603, 1993.						
	A5	Yoko	Yokoyama-Kobayashi et al., <u>Gene</u> 163:193-196, 1995.						
	A6	Marti	Martin et al., Accession No. L35691, 1994.						
	A7	Marti	in et al., Acces	sion No. L35690, 19	994.				
	A8	Marti	in et al., Acces	ssion No. L81573, 19	996.				
	A9	Marti	in et al., Acces	sion No. AC000938	, 1996.				
	A10	Marti	in et al., Acces	sion No. AC000937	, 1996.				
	A11	Cher	et al., Access	sion No. X55448, 19	94.		<u>-</u>		
	A12	Fu a	nd Kamps, <u>Mo</u>	l. Cell. Biol. 17(3):15	503-1512, 1997.			· · · · · · · · · · · · · · · · · · ·	
	A13	Hillie	r, et al., The V	Vash U-Merck EST I	Project, 1995: E	ST180057			
	A14	Hillie	r, et al., The V	Vash U-Merck EST I	Project, 1995: E	ST250901			
	A15	Hillie	r, et al., The V	Vash U-Merck EST I	Project, 1995: E	ST250996			
Examiner	Examiner					ered			
								.P. 609; Draw line ommunication to	

·	U.S.DEPARTMEN' PATENT AND TRA	File No. 97-63C1		Serial No. 10/039,876				
INFORMAÇION DISCL	LOSURE STATEMI	Applicant(s): Darrell C. Conklin, Hal Blumberg						
b 00/ 31 200s 3)	, oral shoots if needs	Filing Date: October 26, 2001		Group: 1646				
TRADEMARK OF	,	U.S. PATENT DOCUMEN	'	,, 2001				
EXAMINER DOCU INITIAL NUMB		Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	FO	REIGN PATENT DOCUM	IENTS					
Examiner DOCU Initial NUMB		COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
				_				
ОТНЕ		(Including Author, Title, I		nt Patents, e	etc.)			
A16	Hillier, et al., The W	Vash U-Merck EST Project, 1995: I	EST304368					
A17	Fujiwara et al., Otsuka cDNA Project, 1996: EST705567							
A18	Hillier, et al., The W	Hillier, et al., The Wash U-Merck EST Project, 1997: EST1043415						
A19	Hillier, et al., The W	Hillier, et al., The Wash U-Merck EST Project, 1997: EST1043487						
A20	Hillier, et al., The W	Vash U-Merck EST Project, 1997: E	ST1043429					
A21	Hillier, et al., The W	Vash U-Merck EST Project, 1997: E	ST1043513					
A22	Strausberg, Nation	al Cancer Institute, Cancer genome	Anatomy Project	ct, 1997: EST11	60316			
A23	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC836786	3			
A24	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC813243	3			
A25	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC94527	1			
A26	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC120858	82			
A27	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC910637	7			
A28	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC947780	0			
A29	LIFESEQ™ Clone	Information Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC151270	01			
Examiner		Date consid	Date considered					
		whether or not citation is in ot considered. Include copy			· · · · · · · · · · · · · · · · · · ·			

FORM PTO 1449 U.S.DEPARTMENT OF COMMERCE (REV 2-32) PATENT AND TRADEMARK OFFICE						7-63C1	Serial No. 10/039,876		
OCT 31 2000 (Use several sheets if necessary)						Applicant(s): Darrell C. Conklin, Hal Blumberg			
OCT 3 7 2005			Filing Date: October 26, 2001		Group: 1646				
PARADEMARK OF			ι	J.S. PATENT DOCUMEN	TS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name	CLASS	FILING DATE IF APPROPRIATE			
	+								
		•	FOI	REIGN PATENT DOCUM	ENTS				
Examiner Initial		DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	ı			Including Author, Title, D					
	A30	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC15468	50		
	A31	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	996: INC16301	76		
	A32		LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996: INC1700802						
	A33	LIFE	LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996: INC1630192						
	A34	LIFE	SEQ TM Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC15017	65		
	A35	LIFE	SEQ [™] Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	1996: INC15818	76		
	A36	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC15018	92		
				<u> </u>					
	A37	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC13184	51		
	A38	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC18560	44		
	A39	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC20601	59		
	A40	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC21801:	23		
	A41	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc.,	1996: INC22739	51		
	A42	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	1997: INC26271	04		
					٠				
	A43	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	1997: INC26458	16		
Examiner	Examiner				lered				
				whether or not citation is in out considered. Include copy					

FORM PTO (REV 2-32)) 144 9		ARTMENT	File No. 97-63C1 Serial No. 10/039,876		Serial No. 10/039,876			
INFORMET	TON I	DISCLOSURE	STATEME	Applicant(s): Darrell C. Conklin, Hal Blumberg					
OCT 81 2	ري دون <i>انگي</i>)		Filing Date October 26		Group: 1646			
OR TRADEN	AFR		τ	TS	·				
EXAMINER DOCUMENT INITIAL NUMBER DATE Name				Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			FOF	REIGN PATENT DOCUM	ENTS				
Examiner Initial		DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	(OTHER DOC	UMENTS (Including Author, Title, D	ate, Pertiner	nt Patents, e	etc.)		
	A44	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	997: INC264030	05		
	A45	LIFE	LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997: INC2920911						
	A46	LIFE	LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997: INC2666840						
	A47	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	997: INC327402	28		
	A48	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	997: INC325500	04		
	A49	LIFE	SEQ™ Clone I	nformation Results, Incyte Pharma	ceuticals, Inc., 1	997: INC32095	19		
	A50	LIFE	SEQ™ Clone li	nformation Results, Incyte Pharma	ceuticals, Inc., 1	997: INC24085	10		
	A51	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: PROSNO	т07		
	A52	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: LUNGNO	T04		
	A53	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: RATRNO	T02		
	A54	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: BRSTNO	T02		
	A55	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: STOMNO)T02		
	A56	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: PANCNO	T05		
	A57	LIFE	SEQ™ Library	Information Results, Incyte Pharma	aceuticals, Inc.,	1996: PANCTU	T01		
Examiner				Date consid	lered				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO (REV 2-32)			PARTMENT Γ AND TRA	File No. 97-63C1		Serial No. 10/039,876				
INFORMAT	I NOB	DISCLOSURE	E STATEME	Applicant(s): Darrell C. Conklin, Hal Blumberg						
OCT 91	2005` *	3		Filing Date: October 26, 2001		Group: 1646				
Filing Date: October 26, 2001 U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
						<u> </u>				
			FOF	REIGN PATENT DOCUM	ENTS					
Examiner Initial		DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	(Including Author, Title, D	•	•	•			
:	A58	LIFE	SEQ™ Library	Information Results, Incyte Pharma	ceuticals, Inc., 1	996: PROSTU	T04			
	A59		LIFESEQ™ Library Information Results, Incyte Pharmaceuticals, Inc., 1996: COLNNOT19							
	A60			Information Results, Incyte Pharma	•					
	A61			Information Results, Incyte Pharma						
	A62			Information Results, Incyte Pharma						
,	A63			Information Results, Incyte Pharma						
	A64			Information Results, Incyte Pharma						
	A65			Information Results, Incyte Pharma						
	A66			Information Results, Incyte Pharma						
	A67			Information Results, Incyte Pharma						
	A68	LIFE	SEQ™ Library	Information Results, Incyte Pharma	ceuticals, Inc., 1	997: OVARTU	T04			
	A69	LIFE	LIFESEQ™ Library Information Results, Incyte Pharmaceuticals, Inc., 1997: LUNGTUT08							
	A70	LIFE	SEQ™ Library	Information Results, Incyte Pharma	ceuticals, Inc., 1	997: SININOT	04			
	A71	LIFE	SEQ™ Library	Information Results, Incyte Pharma	ceuticals, Inc., 1	997: PROSBP	T06			
Examiner				Date conside						
				whether or not citation is in cost considered. Include conv.			· ·			

FORM PTO 1449 U.S.DEPARTMENT OF COMMERCE (REV 2-32) PATENT AND TRADEMARK OFFICE						File No. 97-63C1		Serial No. 10/039,876	
/\Pゟ `		DISCLOSURI		MENT BY APPLIC essary)		Applicant(s): Darrell C. Conklin, Hal Blumberg			
OCT 3 1 200	(پير ن				Filing Date: October 26,		Group: 1646		
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name		CLASS SUBCLASS		FILING DATE IF APPROPRIATE	
			F(OREIGN PATEN	T DOCUME	NTS			
Examiner Initial		DOCUMENT NUMBER	Date	COUNTRY		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
				S (Including Auth	•	•	•	•	
	A72	LIFE	ESEQ™ Libra	ary Information Results,	Incyte Pharmaco	euticals, Inc., 1	997: OVARTU	JN01	
	A73	LIFE	ESEQ™ Libra	ary Information Results,	Incyte Pharmace	euticals, Inc., 1	997: BLADNO)T08	
	A74	A74 LIFESEQ TM Library Information Results, Incyte Pharmaceuticals, Inc., 1997: BSTMNON02							
	A75	Yoo	n et al., <u>Struc</u>	eture 13:551-564, 2005.					
	A76	Pes	tka et al., <u>Imr</u>	nunological Reviews 20	02:8-32, 2001.				
	A77	Trin	chieri, <u>Immun</u>	nological Reviews 202:5	5-7, 2001.				
	A78	Cha	ing et al., <u>Leu</u>	kemia <u>17</u> :1263-1293, 2	003.				
	A79	Sch	ein, <u>Current F</u>	Pharmaceutical Design	<u>10(31</u>):3853-385	5, 2004.			
									
				- -					
			<u> </u>						
Examiner					Date consider	red			
EVAMINE	D. Ini	tial if aitation		L whether or not ci	tation is in as	nformanaa	with M D E	P. 600: Draw line	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.